You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Renal cancer

Lenvatinib with everolimus for previously treated advanced renal cell carcinoma

  • Technology appraisal guidance
  • Reference number: TA498
  • Published:  24 January 2018
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Expected publication
  2. Final appraisal determination
  3. Draft guidance
  4. Invitation to participate

History

Documents created during the development process.

Expected publication

  • Equality Impact Assessment (Guidance development) (PDF 237 KB)

    Published:
    16 February 2018

Final appraisal determination

  • Final appraisal determination

  • Final appraisal determination document (PDF 389 KB)

    Published:
    08 December 2017
  • Committee papers (PDF 1.5 MB)

    Published:
    08 December 2017
  • Public committee slides (PDF 502 KB)

    Published:
    08 December 2017

Draft guidance

  • Draft guidance

  • Appraisal consultation document (PDF 394 KB)

    Published:
    11 August 2017
  • Committee papers (PDF 7.01 MB)

    Published:
    11 August 2017
  • Public committee slides (PDF 1.33 MB)

    Published:
    11 August 2017

Invitation to participate

  • Final scope (PDF 224 KB)

    Published:
    09 February 2017
  • Final matrix (PDF 258 KB)

    Published:
    09 February 2017
  • NICE's response to comments on the draft scope and provisional matrix (PDF 232 KB)

    Published:
    09 February 2017
  • Equality impact assessment (Scoping) (PDF 175 KB)

    Published:
    09 February 2017
Back to top